Shareholder pressures Capricor; Lilly dives deeper into vaccines

Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders

Capricor Draws Investor Attention As Shareholder Kaos Capital Pushes For Board Shakeup Ahead Of Key FDA Decision On DMD Therapy

CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel

FDA extends review of Capricor cell therapy; Pain drug startup to go public

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

Capricor Therapeutics Deramiocel PDUFA Date Extended to November as FDA Reviews BLA Amendment

Why Is CAPR Stock Rising Today?

Sector Update: Healthcare Stocks Decline in Afternoon Trading

CAPR Stock Climbs On FDA’s Three-Month Deramiocel Extension — HC Wainwright Sticks To Neutral, Flags High Rejection Risk